Please login to the form below

2019: A pivotal year for the NHS

Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the key changes in the NHS in 2019

Introduction

At the start of 2019, the NHS set out its priorities in its highly anticipated ‘Long-term Plan’, which provides a blueprint for the design and delivery of NHS services over the next 10 years.

The plan, which reaffirmed the NHS’s commitment to integrated care, has prompted significant changes with regards to structure; finance; commissioning; outcomes and key performance indicators (KPIs).

Structure

The Long-term Plan stated that, by April 2021, all areas of England will be covered by an Integrated Care System (ICS), with typically just one Clinical Commissioning Group (CCG) per ICS area. In June, three further areas were designated as ICSs by NHS England. CCG mergers have continued in 2019 and it is possible that, ultimately, there could be a reduction from the current 191 CCGs to around 60-70.

The introduction of Primary Care Networks (PCNs) in July, which are the building blocks for Integrated Care Providers and Partnerships (ICPs), was another fundamental structural change.

Finance

Some ICSs have already dispensed with standard Payment by Results (PBR) contracts and are operating more integrated budgets or block contracts. These systems are trailblazers which all other health systems are under pressure to emulate within the next few years.

The move from PBR to variable, outcomes-based and block contracts is creating a more complicated landscape in terms of the relationship and money flow between commissioners and providers, and also from the perspective of understanding how PCNs and ICPs take on some of the lower level commissioning and contracting functions of CCGs.

A knock-on effect of outcomes-based and block contracts, and the integrated approach that underpins them, is that hospitals will no longer compete against each other.

Commissioning and hospitals

Although the NHS is committed to ICSs, in some parts of the country, such as London, which have large and long-established teaching hospitals, it is likely that these hospitals will drive the local care agenda. These hospitals will still have a fixed budget for providing local services and they will have to determine how to manage it.

Also on the hospital theme, in a bid to improve surgical services, the Long-term Plan promised to continue backing hospitals that wish to separate urgent and planned care into different sites which are known respectively as ‘hot’ and ‘cold’ sites, and this style of working has been increasing this year e.g. in North Tyneside.

Bringing care closer to home

Reducing hospital stays and bringing care closer to home are key objectives in the Long-term Plan and also its predecessor, the Five Year Forward View. Some innovative healthcare organisations have already successfully shown how it can be achieved. For example, Calderdale and Huddersfield NHS Foundation Trust has a day-case digital knee replacement surgery where some patients can have an operation and be discharged within 24 hours. Rehabilitation therapists can then remotely monitor the patient’s progress at home, via wearable technology in the form of a sensor worn by the patient.

System-Wide Key Performance Indicators (KPIs)

The NHS Oversight Framework (OF) for 2019/20 has replaced the provider Single Oversight Framework for hospitals and the CCG Improvement and Assessment Framework (IAF), which set annual targets for CCGs. It means that hospitals and CCGs must now work together to deliver on KPIs across their STP/ICS footprint.

Under the OF, KPIs are being set for individual disease areas. For example, indicators and targets have been set for around 20 different areas for cancer.

Market Access

Post-election, all health economies are due to publish new plans for their localities in response to the Long-term Plan. The deadline for these plans was originally set for mid-November but it has since been extended for at least another month.

The new plans are highly significant since they may impact on which drugs are used and how care pathways are provided. This means that, to a large extent, we are ending the year on a ‘wait and see’ basis.

It will be essential for pharma to conduct a locality by locality analysis of the new STP/ICS long term plans to define how clinicians fit into networks and who will be in the new decision-making units.  Pharma also needs to identify the clinical leaders who are tasked with managing transformation and who will be leading workstreams.

Pharma should also follow the specialist organisations that are working alongside ICSs and STPs on specific disease areas, such as Cancer Alliances.

Conclusion

There are golden opportunities for pharma to support local health economies in delivering key elements of the Long-term Plan. But the local NHS landscape is becoming increasingly complex and more change is on the horizon.

Pharma needs to take an increasingly tailored approach to customer engagement in 2020 and seek to understand the goals and aspirations of individual health economies as they continue to evolve in line with the NHS’s long-term vision.

Ends

Paul Midgley is Director of NHS Insight and Oli Hudson is Content Director, both at Wilmington Healthcare. For information on Wilmington Healthcare and to find out more about the latest developments in the NHS, including the role of PCNs, visit www.wilmingtonhealthcare.com

19th December 2019

Share

Company Details

Wilmington Healthcare

01268 495600

Contact Website

Address:
Beechwood House
2-3 Commercial Way
Christy Close
Southfields
Basildon
SS15 6EF
United Kingdom

Latest content on this profile

UNDERSTANDING THE ROLE OF PLACE WITHIN THE NEW NHS: FIVE THINGS INDUSTRY NEEDS TO KNOW
Operating a level below system, “place” is an increasingly important unit of NHS organisation, yet it remains an evolving concept that is not always well-understood among industry practitioners. In this latest quick-read briefing, Oli Hudson, Content Director at Wilmington Healthcare, lifts the veil on what place is, how it works and why it matters.
Wilmington Healthcare
MISSION CRITICAL: HOW PHARMA CAN HELP THE NHS IMPROVE CARE FOR OLDER PEOPLE
With around two-thirds of all hospital beds occupied by over-65s, the care of older patients has long been recognised as key to the sustainability of the NHS. So how is it responding to this challenge, and what can industry do to support it? Oli Hudson, Content Director at Wilmington Healthcare, explains what’s changing and how industry should respond.
Wilmington Healthcare
ALL CHANGE FOR SPECIALISED COMMISSIONING: FOUR THINGS INDUSTRY NEEDS TO KNOW ABOUT THE LATEST REFORMS
With a recent NHSEI policy document confirming that a major shake-up of arrangements for Specialised Commissioning is imminent, Oli Hudson, Content Director at Wilmington Healthcare (wilmingtonhealthcare.com), describes the key changes and why they matter for pharma and med-tech companies.
Wilmington Healthcare
HOW DID COVID-19 AFFECT PRESCRIBING BEHAVIOURS? FIVE KEY FINDINGS FROM A NEW STATE OF THE NATION REVIEW
Published earlier this month, Wilmington Healthcare’s new State of the Nation report draws on a raft of data from across primary and secondary care to show what actually happened to the NHS and its prescribing behaviours during the peak of the pandemic.  Oli Hudson summarises five of the key findings:
Wilmington Healthcare
ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE
With the Health and Care Act safely passed, Oli Hudson introduces six key stakeholders that will loom large in the new landscape.
Wilmington Healthcare
Spending on anti-depressants soars as the pandemic’s effect on NHS prescribing patterns is revealed

Wilmington Healthcare